ArticleInternational journal of clinical and experimental pathology2018
microRNA-134 inhibits melanoma growth and metastasis by negatively regulating collagen triple helix repeat containing-1 (CTHRC1).
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- The Roles of MiRNAs (MicroRNAs) in Melanoma Immunotherapy.International journal of molecular sciences · 2022Pooled it
- Review
- The role of collagen triple helix repeat containing 1 (CTHRC1) in cancer development and progression.Expert opinion on therapeutic targets · 2024Review
- CTHRC1, a novel gene with multiple functions in physiology, disease and solid tumors (Review).Oncology letters · 2023Review
- miR-509-3p Suppresses Migration, Invasion, and Epithelial- Mesenchymal Transition in Melanoma Cells by Targeting Collagen Triple Helix Repeat Containing 1.Balkan medical journal · 2021Article
- MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets.Frontiers in oncology · 2021Review
- The microRNA miR-134-5p induces calcium deposition by inhibiting histone deacetylase 5 in vascular smooth muscle cells.Journal of cellular and molecular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melanoma, a malignant tumor of melanocytes, is considered to be the most aggressive of skin cancers and its incidence keeps increasing worldwide. miR-134 and CTHRC1 have been demonstrated to be involved in the occurrence and development of various tumors. However, their roles are still elusive in the progression of melanoma. qRT-PCR and western blot (WB) were used to examine the expressions of miR-134 and CTHRC1 in clinical specimens of melanoma patients and melanoma cell lines. Dual-luciferase reporter assay was applied to verify the target interaction between miR-134 and CTHRC1. The mRNA and protein expressions of CTHRC1 were measured by qRT-PCR and WB after treatment by miR-134 inhibitor and mimic. Subsequently, CCK8, colony formation assay, and flow cytometry were utilized to assess the influences of miR-134 and CTHRC1 on cell growth of melanoma. Cell migration and invasion experiments were performed to evaluate the effects of miR-134 and CTHRC1 on metastasis of melanoma. It was shown that CTHRC1 was up-regulated and miR-134 was down-regulated in melanoma patients and cell lines. CTHRC1 was demonstrated to be a direct target of miR-134. Ultimately, we also found that up-regulated miR-134 expression and down-regulated CTHRC1 expression could suppress cell proliferation and cell colony formation, promote apoptosis, delay the cell cycle, and hinder cell migration and invasion. Our findings suggest that miR-134 could inhibit the growth and metastasis of melanoma by negatively regulating CTHRC1.
Indexed as
Identifiers
31949828PMC6962948W3027781201What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.